Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2125|79|5|789-800

ISSN： 0306-5251

Source： BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.79, Iss.5, 2015-05, pp. : 789-800

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 2, 2018-02 ,pp. : 180-192

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population Pharmacokinetic Analysis of Linezolid in Low Body Weight Patients with Renal Dysfunction

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 53, Iss. 9, 2013-09 ,pp. : 967-973

John Wiley & Sons Inc

Access to resources Recommend Favorite

SOP 14: Population Pharmacokinetic Analysis

By  

Oncology Research and Treatment, Vol. 26, Iss. 6, 2004-11 ,pp. : 60-66

Karger

Access to resources Recommend Favorite

Memantine Standard Tablet and Extended‐Release Dosing Considerations: A Pharmacokinetic Analysis

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 63, Iss. 2, 2015-02 ,pp. : 383-384

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vigabatrin pediatric dosing information for refractory complex partial seizures: Results from a population dose–response analysis

By  

EPILEPSIA, Vol. 55, Iss. 12, 2014-12 ,pp. : e134-e138

John Wiley & Sons Inc

Access to resources Recommend Favorite